First human trial launches for Next-Generation mRNA HIV vaccines

NCT ID NCT07390474

Summary

This is a first-in-human, early-stage trial to test the safety and immune response of two new experimental HIV vaccines. The vaccines, called DV201P-RNA and DV202B1-RNA, use mRNA technology (similar to some COVID-19 vaccines) to train the immune system to fight HIV. The study will enroll 40 healthy adult volunteers who do not have HIV to receive the vaccines and be closely monitored.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Columbia P&S CRS

    New York, New York, 10032, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Penn Prevention CRS

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Hope Clinic of the Emory Vaccine Research Center; Emory University

    Decatur, Georgia, 30030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Ponce de Leon Center CRS

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pittsburgh CRS

    Pittsburgh, Pennsylvania, 15213, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Rochester Vaccines to Prevent HIV Infection CRS

    Rochester, New York, 14642, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.